

(EUR)	31/12/2023	31/12/2022
Assets		
Fixed assets	37 118,83	44 372,47
III. Tangible fixed assets	33 718,83	40 672,47
B. Plant, machinery and equipment	33 470,16	40 164,12
C. Furniture and vehicles	248,67	508,35
IV. Financial fixed assets	3 400,00	3 700,00
C. Other financial fixed assets	3 400,00	3 700,00
2. Amounts receivable and cash guarantees	3 400,00	3 700,00
Current assets	932 781,72	1 031 799,30
VII. Amounts receivable within one year	5 000,00	7 041,26
B. Other amounts receivable	5 000,00	7 041,26
IX. Cash at bank and in hand	911 931,72	1 024 758,04
X. Accruals and deferred income	15 850,00	0,00
Total assets	969 900,55	1 076 171,77
Equity and liabilities		
Equity	923 176,02	831 232,10
III. Reserves	83 470,16	103 552,00
A. Reserves not available	83 470,16	103 552,00
4. Other	83 470,16	103 552,00
IV. Accumulated profits (+)/ losses (-)	839 705,86	727 680,10
Amounts payable	46 724,53	244 939,67
IX. Amounts payable within one year	29 724,53	34 273,00
C. Trade debts	5 701,49	4 818,12
1. Suppliers	5 701,49	4 818,12
E. Taxes, remuneration and social security	24 023,04	29 454,88
1. Taxes	12 349,03	18 415,19
2. Remuneration and social security	11 674,01	11 039,69
X. Accruals and deferred income	17 000,00	210 666,67
Total liabilities	969 900,55	1 076 171,77
Profit and loss account		
I. Operating income	870 277,66	577 527,86
A. Turnover	869 802,42	577 527,86
D. Other operating income	475,24	0,00
II. Operating charges	768 735,84	584 182,05
A. Goods for resale, raw materials and consumables	504 522,94	397 722,01
1. Purchases	504 522,94	397 722,01

B. Services and other goods	175 932,29	114 764,08
C. Remunerations, social security costs and pensions	78 993,13	64 489,49
D. Amortisations of and other amounts written down on formation expenses, intangible and tangible fixed assets	6 953,64	6 953,64
G. Other operating charges	2 333,84	252,83
III. Operating profit/loss	101 541,82	-6 654,19
IV. Financial income	8 919,08	16 278,71
A. Income from financial fixed assets	242,92	0,00
C. Other financial income	8 676,16	16 278,71
V. Financial charges	18 516,98	2 737,82
A. Debt charges	2 806,48	0,00
C. Other financial charges	15 710,50	2 737,82
VI. Profit/loss of the period before taxes	91 943,92	6 886,70
IX. Profit/loss of the period	91 943,92	6 886,70
X. Transfer from/to untaxed reserves	20 081,84	0,00
A. Transfer from untaxed reserves	20 081,84	0,00
XI. Profit/loss of the period available for appropriation	112 025,76	6 886,70
Appropriation account	0,00	0,00
A. Profit/loss to be appropriated	839 705,86	727 680,10
1. Profit/Loss of the period available for appropriation	112 025,76	6 886,70
0. Profits/loss of the preceding period brought forward	727 680,10	720 793,40
D. Profit/loss to be carried forward	839 705,86	727 680,10
1. Profit to be carried forward	-839 705,86	-727 680,10

REVENUE 2023				
INDUSTRY related	Support			
AstraZeneca	60.000,00 €	10%		
Alexion	41.000,00 €	7%		
BI	90.000,00 €	16%		
BMS	13.000,00 €	2%		
Bayer	10.000,00 €	2%		
CymaBay	8.000,00 €	1%		
Cellaion	5.000,00 €	1%		
Gilead	146.666,67 €	26%		
IPSEN	32.000,00 €	6%		
GSK	15.000,00 €	3%		
Mirum	8.000,00 €	1%		
Novonordisk	94.950,00 €	17%		
Roche	50.000,00 €	9%		
TOTAL	573.616,67 €	100%	66%	
NON INDUSTRY related				
EU PROJECTS				
Genial	29.181,25 €	10%		
A-Tango	15.953,61 €	5%		
Liveration	44.625,00 €	15%		
FisPlat	33.567,63 €	11%		
IPCureB	50.071,05 €	17%		
Decision	14.053,64 €	5%		
Leopard	29.093,75 €	10%		
MEMBERSHIP	- €	0		
OTHER	79.639,82 €	27%		
TOTAL	296.185,75 €	100%	34%	
TOTAL	869.802,42 €			100%